Gene Therapy, more than ever-a new vision for the journal.
作者信息
Yáñez-Muñoz R J
机构信息
AGCTlab.org, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK.
出版信息
Gene Ther. 2017 Sep;24(9):493-494. doi: 10.1038/gt.2017.60.
PMID:28963565
Abstract
摘要
相似文献
1
Gene Therapy, more than ever-a new vision for the journal.基因治疗，比以往任何时候都更具意义——该期刊的全新愿景。
Gene Ther. 2017 Sep;24(9):493-494. doi: 10.1038/gt.2017.60.
2
Compilation of online resources of relevance to 'Spinraza and advanced therapies: a stakeholder special' issue of Gene Therapy.与《基因治疗》“Spinraza与先进疗法：利益相关者特刊”相关的在线资源汇编
Gene Ther. 2017 Sep;24(9):599. doi: 10.1038/gt.2017.61.
3
FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.美国食品药品监督管理局批准诺西那生用于治疗脊髓性肌萎缩症，使2016年成为剪接调节寡核苷酸之年。
Nucleic Acid Ther. 2017 Apr;27(2):67-69. doi: 10.1089/nat.2017.0665. Epub 2017 Feb 21.
4
New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.脊髓性肌萎缩症的新疗法性价比不高。
Manag Care. 2017 Feb;26(2):36-37.
5
Spinraza-a rare disease success story.Spinraza——罕见病治疗的成功案例。
Gene Ther. 2017 Sep;24(9):497. doi: 10.1038/gt.2017.59.
6
Spinraza-the patient perspective.Spinraza——患者视角
Gene Ther. 2017 Sep;24(9):501-502. doi: 10.1038/gt.2017.56. Epub 2017 Sep 7.
7
News Feature: Gene therapy successes point to better therapies.新闻特写：基因治疗的成功预示着更好疗法的出现。
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):23866-23870. doi: 10.1073/pnas.1918306116.
8
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.用于脊髓性肌萎缩症的Spinraza（诺西那生钠）的市场准入：知识产权、定价、价值及覆盖范围考量
Gene Ther. 2017 Sep;24(9):539-541. doi: 10.1038/gt.2017.79. Epub 2017 Sep 7.
9
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.诺西那生钠，一种用于治疗脊髓性肌萎缩症的反义寡核苷酸药物。
Nat Neurosci. 2017 Apr;20(4):497-499. doi: 10.1038/nn.4508. Epub 2017 Feb 13.
10
Nusinersen helps restore walking ability in childhood spinal muscular atrophy.诺西那生钠有助于恢复儿童脊髓性肌萎缩症患者的行走能力。
Pediatr Int. 2019 Jul;61(7):728-729. doi: 10.1111/ped.13867. Epub 2019 Jul 9.
引用本文的文献
1
An Induced Pluripotent Stem Cell-Derived Human Blood-Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides.一种用于测试腺相关病毒（AAV）载体和反义寡核苷酸穿越能力的诱导多能干细胞衍生的人血脑屏障（BBB）模型。
Biomedicines. 2023 Oct 4;11(10):2700. doi: 10.3390/biomedicines11102700.
Zotero 插件